JP2018503685A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503685A5
JP2018503685A5 JP2017556784A JP2017556784A JP2018503685A5 JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5 JP 2017556784 A JP2017556784 A JP 2017556784A JP 2017556784 A JP2017556784 A JP 2017556784A JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
net
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013847 external-priority patent/WO2016118476A1/en
Publication of JP2018503685A publication Critical patent/JP2018503685A/ja
Publication of JP2018503685A5 publication Critical patent/JP2018503685A5/ja
Pending legal-status Critical Current

Links

JP2017556784A 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 Pending JP2018503685A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105342P 2015-01-20 2015-01-20
US62/105,342 2015-01-20
PCT/US2016/013847 WO2016118476A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Publications (2)

Publication Number Publication Date
JP2018503685A JP2018503685A (ja) 2018-02-08
JP2018503685A5 true JP2018503685A5 (enExample) 2019-02-21

Family

ID=56417634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556784A Pending JP2018503685A (ja) 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物

Country Status (5)

Country Link
US (3) US11400139B2 (enExample)
EP (2) EP3797789B1 (enExample)
JP (1) JP2018503685A (enExample)
CA (1) CA2974369A1 (enExample)
WO (1) WO2016118476A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
UA129696C2 (uk) 2017-08-18 2025-07-09 Ньютроліс Інк. СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ
EP3761971A4 (en) * 2018-03-09 2021-11-10 The University of Memphis Research Foundation FLAMMATION INHIBITION COMPOSITIONS AND METHODS
US12480150B2 (en) 2018-06-29 2025-11-25 Viktor Veniaminovich Tets and Georgy Viktorovich TETS Compositions for modulating gut microbiota
KR20220092493A (ko) 2019-09-06 2022-07-01 콘세호 나시오날 데 인베스티가시오네스 시엔티피카스 이 테크니카스 (코니셋) 국소 상처 치료용 약학적 조성물
GB202012326D0 (en) * 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统
KR102961523B1 (ko) * 2022-08-08 2026-05-11 재단법인 아산사회복지재단 Pad 저해제를 포함하는 퇴행성 판막 질환의 예방 또는 치료용 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6919320B1 (en) * 1987-10-28 2005-07-19 Wellstat Therapeutics Corporation Pharmaceutical compositions containing deoxyribonucleosides for wound healing
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
JP3162372B2 (ja) 1988-12-23 2001-04-25 ジェネンテク，インコーポレイテッド ヒトｄｎアーゼ
DE3903672C1 (enExample) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5539878A (en) 1995-06-16 1996-07-23 Elonex Technologies, Inc. Parallel testing of CPU cache and instruction units
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
AU3243300A (en) 1999-02-23 2000-09-14 Isis Pharmaceuticals, Inc. Multiparticulate formulation
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
JPWO2005075414A1 (ja) 2004-02-04 2007-10-11 公立大学法人横浜市立大学 ペプチジルアルギニンデイミナーゼ４阻害剤
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007056389A2 (en) 2005-11-07 2007-05-18 University Of South Carolina Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
CA2720301C (en) 2008-04-03 2017-11-07 Kane Biotech Inc. Dispersinb tm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
BRPI0915336A2 (pt) 2008-06-16 2017-06-27 Academisch Ziekenhuis Leiden composto capaz de inibir a atividade de uma pad, composição, e, uso de um composto
WO2012166611A2 (en) * 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
CA2911483C (en) 2013-04-09 2022-10-04 The University Of Tokyo Inhibitor of extracellular trap formation in leukocytes
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
WO2014206856A1 (en) * 2013-06-24 2014-12-31 Dentsply Ih Ab Medical device comprising collagen-vi

Similar Documents

Publication Publication Date Title
Neckers et al. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
EP4230623A3 (en) Pyridine compounds as allosteric shp2 inhibitors
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
CN111868056A (zh) 1,2,4-噁二唑类化合物及其制备方法和医药用途
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
JP2007523049A5 (enExample)
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
RU2018121036A (ru) Комбинированная пре- и пробиотическая композиция
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
JP2020507587A5 (enExample)
PH12020551905A1 (en) C-mannoside compounds useful for the treatment of urinary tract infections
RU2018124487A (ru) Лечение внутрипеченочного холестаза и родственных заболеваний печени
JP2020111586A5 (enExample)
Garrido et al. Medical course and complications after lung transplantation
CY1125769T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν εναν αναστολεα αποακετυλασης ιστονων και εναν αναστολεα bcl-2 και μεθοδοι χρησης αυτων
JP2021514365A5 (enExample)
JP2017536380A5 (enExample)
JP2019533715A5 (enExample)
EP4297765A4 (en) COMPOSITION FOR THE TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONS
Jørgensen et al. Isotretinoin and hidradenitis suppurativa.
JP2020523375A5 (enExample)
MX421623B (es) Composiciones para tratar enfermedades pulmonares crónicas
JP2020527138A5 (enExample)
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle
WO2023166318A3 (en) Therapeutic antibodies